A new human trial published in Cannabis and Cannabinoid Research has provided the most comprehensive look yet at the safety and effects of Δ8-Tetrahydrocannabivarin (THCV), a lesser-known cannabinoid that has gained popularity for its supposed energizing properties.
The study examined a wide range of oral doses of THCV, finding that the compound was well tolerated up to 200 milligrams, with only mild adverse effects reported.
Researchers conducted the study in two phases involving 21 healthy adults. The first phase used a single-ascending dose design, while the second was a double-blind, randomized crossover trial where participants received placebo as well as 12.5, 25, 50, 100, and 200 mg doses of THCV. Safety, subjective experience, and cognitive performance were measured over an eight-hour period after dosing.
The safety results were consistent across all doses. Out of 60 reported adverse events, 55 were rated mild, with no serious events observed. The most common effect was euphoric mood, followed by headaches, though these were not strictly dose dependent. Only one participant withdrew due to nausea at the 100 mg dose. Importantly, no abnormalities were seen in vital signs, physical exams, or electrocardiograms.
When it came to subjective effects, lower doses such as 25 mg showed modest but non-significant increases in self-reported energy. Higher doses of 100 and 200 mg, however, led to clear increases in ratings of “feeling a drug effect” and “liking the drug effect.” These higher doses also produced mild THC-like effects without measurable impairment. On cognitive testing, the 12.5, 25, and 200 mg doses significantly improved sustained attention on a digit vigilance test, though the effect was not dose dependent.
One of the more surprising findings came from urine drug screens. Nearly all participants who received THCV tested positive for THC at the eight-hour mark, despite the product containing no detectable THC. Researchers suggest this is due to cross-reactivity in drug tests caused by THCV’s structural similarity to THC or its metabolites. This raises an important caution for consumers: taking THCV products could lead to a positive THC drug test result.
The study adds weight to prior small-scale findings suggesting THCV has a good safety profile, but it is the first to systematically test a broad range of doses. Researchers note that the results align with animal studies showing dose-dependent effects, with lower doses potentially acting as CB1 antagonists and higher doses producing agonist-like activity similar to THC. While encouraging, the authors caution that the trial was exploratory and not powered to establish statistical significance for all observed effects. Larger and longer-term studies are needed to confirm the safety of repeated dosing, clarify the dose-response curve, and assess whether THCV carries any abuse potential.
With a growing number of THCV-infused products already available on the U.S. market, these findings provide early reassurance about safety but also highlight key unknowns. Consumers may indeed experience mild stimulation or focus at some doses, but at higher amounts they may also encounter THC-like effects—and unintended drug test consequences. Future research will be crucial to establish exactly where THCV fits among the dozens of cannabinoids produced by the cannabis plant.
Sponsored
